L&J Bio is committed to developing therapeutic proteins for neurodegenerative diseases through our Dual Action Therapy(DAT) Platform. We have developed innovative therapeutics for Alzheimer's disease through the application of our fusion proteins and implementing DAT to target both amyloid beta and phosphorylated tau proteins.
Our mission is to provide safe and effective therapies for patients with serious illnesses.
Head quarters and research institute is located in Seoul, South Korea, while research institute/cGMP facility(future) is in Maryland, United States. L&J Bio submitted the Pre-IND package to the U.S. FDA.
Company Details
- Employees
- 16
- Founded
- -
- Address
- 128, Beobwon-Ro,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.lnjbio.com
- Keywords
- neurodegenerative disease, therapeutics, Drug development, AlzheimersResearch, Innovation, HealthcareLeadershi, amyloid-beta, p-tau proteins, Dual Action Therapy Platform, Fusion Therapeutic Protein, Blood-Brain Barrier (BBB) Penetration, Cystatin C, Human Serum Albumin, Cell Penetrating Peptide.
- HQ
- Seoul
L&j Bio, Co.,ltd. Questions
L&J Bio, Co.,Ltd.'s website is http://www.lnjbio.com
L&J Bio, Co.,Ltd.'s LinkedIn profile is https://www.linkedin.com/company/lnjbio
L&J Bio, Co.,Ltd. has
16 employees.
View email and phone details for 16
employees at L&J Bio, Co.,Ltd..
L&J Bio, Co.,Ltd.'s industry is
Biotechnology Research
L&J Bio, Co.,Ltd.'s top competitors are
Biontech Se,
Mesa Systems Co.,
Unicosearch (유니코써치),
Xpressbio,
Valogic Bio,
M&k Biosciences, Inc.,
L&j Biotech,
Kemp Proteins,
Centella,
Salubris Biotherapeutics.
L&J Bio, Co.,Ltd.'s categories are Biotechnology Research
L&J Bio, Co.,Ltd.'s founding year is 2012
